(Q41346437)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9025785%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

review article

1 reference

title

Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9025785%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9025785%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

J Vinholes

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9025785%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

R Coleman

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9025785%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 July 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9025785%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

published in

Cancer Treatment Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9025785%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9025785%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9025785%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

289-331

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9025785%20AND%20SRC:MED&resulttype=core&format=json

The clinical course of bone metastases from breast cancer

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

The biosynthesis of collagen and its disorders (first of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Post-translational processing of procollagens

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Quasi-hexagonal molecular packing in collagen fibrils

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Isolation and characterization of a fluorescent material in bovine achilles tendon collagen

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Pyridinoline, a non-reducible crosslink of collagen. Quantitative determination, distribution, and isolation of a crosslinked peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

A novel fluor in insoluble collagen: a crosslinking moiety in collagen molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

The chemistry of the collagen cross-links. The mechanism of stabilization of the reducible intermediate cross-links

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Cross-linking in collagen and elastin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Cross-linking of collagen. Location of pyridinoline in bovine articular cartilage at two sites of the molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Locus of a histidine-based, stable trifunctional, helix to helix collagen cross-link: stereospecific collagen structure of type I skin fibrils

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Relation between serum and urinary calcium with particular reference to parathyroid activity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Metabolic effects of pamidronate in patients with metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Biochemical prediction of response of bone metastases to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Estimation of whole body bone resorption rate: A comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Nondialyzable Urinary Hydroxyproline as an Index of Bone Collagen Formation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

The clinical measurement of urinary total hydroxyproline excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Modifications of a specific assay for hydroxyproline in urine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

An easy and reliable method for determination of urinary hydroxyproline

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Hydroxyproline in the early diagnosis of bone metastases in prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Urine Hydroxyproline Excretion-a Marker of Bone Metastases in Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Serum osteocalcin concentration in patients with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Early morning hydroxyproline excretion in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Assessment of response of bone metastases to systemic treatment in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Posture, age, menopause, and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium crosslinks

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Biological variation in urinary excretion of pyridinium crosslinks: recommendations for the optimum specimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Biochemical markers of bone turnover in girls during puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Urinary excretion of pyridinium cross-links in healthy women; the long-term effects of menopause and oestrogen/progesterone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Analysis of pyridinoline, a cross-linking compound of collagen fibers, in human urine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Rapid assay for hard tissue collagen cross-links using isocratic ion-pair reversed-phase liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

An enzyme-linked immunoassay for the collagen cross-link pyridinoline

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Assay of pyridinium crosslinks in serum using narrow-bore ion-paired reversed-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Determination of pyridinium crosslinks in plasma and serum by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

High-performance liquid chromatographic determination of pyridinium crosslinks in serum, urine and dialysate of patients in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Pyridinium crosslinks as markers of bone resorption in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

[Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate of bone resorption: usefulness of urinary pyridinoline and deoxypyridinoline in patients with prostate cancer with bone metastases]

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Generalised increase in bone resorption in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Parathyroid hormone related protein and hypercalcaemia in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Changes of bone metabolic markers in patients with bone metastases: clinical significance in assessing bone response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Decreased bone turnover in oral contraceptive users

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Acute effects of bisphosphonates on new and traditional markers of bone resorption.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Monitoring of free and total urinary pyridinoline and deoxypyridinoline in healthy volunteers: sample relationships between 24-h and fasting early morning urine concentrations.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by chromatographic and immunoassay methods.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Immunoassay for urinary pyridinoline: the new marker of bone resorption

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: Results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Efficacy of simultaneous determination of bone alkaline phosphatase mass concentration in serum and urinary excretion of pyridinium cross-links for detection of bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Bone metabolic markers in bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Collagen derived serum markers in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Acute effects of high-dose chemotherapy followed by bone marrow transplantation on serum markers of bone metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Urinary metabolites of collagen

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Variations in human urinary O-hydroxylysyl glycoside levels and their relationship to collagen metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Metabolism of osteocalcin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Effect of renal function on plasma levels of bone Gla-protein

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Seasonal variation in bone metabolism in young healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Elderly women in northern New England exhibit seasonal changes in bone mineral density and calciotropic hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Effect of short-term glucocorticoids on serum osteocalcin in healthy young men.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Osteocalcin: a potential marker of metastatic bone disease and response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Serum osteocalcin levels in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Clodronate treatment increases serum osteocalcin in normocalcemic osteolytic bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Treatment of bone metastases with dichloromethylene bisphosphonate.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Serum osteocalcin (BGP) in tumor-associated hypercalcemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone Gla-protein

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Diurnal rhythm in serum activity of wheat-germ lectin-precipitable alkaline phosphatase: temporal relationships with the diurnal rhythm of serum osteocalcin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

A simplified heat-inactivation method for investigating alkaline phosphatase isoenzymes in serum

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Quantitative method for determining serum alkaline phosphatase isoenzyme activity I. Guanidine hydrochloride: new reagent for selectively inhibiting major serum isoenzymes of alkaline phosphatase

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Biochemical picture accompanying sclerotic bone metastases of prostatic origin.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

New and traditional serum markers of bone metabolism in the detection of skeletal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Serum bone alkaline phosphatase and CA 549 in breast cancer with bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Osseous metastases of breast cancer. Clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Transient increase in total serum alkaline phosphatase predicts radiological response to systemic therapy in breast cancer patients with osteolytic and mixed bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Prostatic cancer with bone metastases: serum alkaline phosphatase (SAP) as a predictor of response and the significance of the SAP "flare"

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Diagnostic value of serum procollagen peptide measurements in alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Radioimmunoassay for Human Procollagen

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type I collagen

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Serum levels of carboxyterminal propeptide of type I procollagen in cancer patients with osteoblastic and osteolytic bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Bone formation markers and pain palliation in bone metastases treated with strontium-89

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

The radiological demonstration of osseous metastases. Experimental observations

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

The role of computed tomography in the detection of bone metastases in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

MRI in the detection of malignant infiltration of bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Early MR demonstration of spinal metastases in patients with normal radiographs and CT and radionuclide bone scans

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Magnetic resonance imaging in the detection of skeletal metastases in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Radiographic evaluation of therapeutic response in bony metastases of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

Bone metastases and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990021-3

7 January 2021

10.1016/S0305-7372(96)90021-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9025785%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference